Kevin Obrien, MD
Family Medicine · Norman, OKNPI 1780610717
Payments from drug & device makers
Across 169 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$697
- GSK$452
- Lilly USA, LLC$282
- AbbVie$271
- Sunovion Pharmaceuticals Inc.$254
- Pfizer$246
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,450100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $697 |
| GSK | 21 | $452 |
| Lilly USA, LLC | 19 | $282 |
| AbbVie | 10 | $271 |
| Sunovion Pharmaceuticals Inc. | 7 | $254 |
| Pfizer | 15 | $246 |
| Novo Nordisk | 16 | $217 |
| Astellas Pharma US Inc | 9 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
| Amgen | 7 | $122 |
| Idorsia Pharmaceuticals US Inc | 1 | $69 |
| Exact Sciences | 3 | $53 |
| Amarin Pharma, Inc. | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Mylan Specialty L.p. | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Ironwood Pharmaceuticals, Inc | 2 | $32 |
| Medtronic | 1 | $32 |
| Optinose US, Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $29 |
| Corcept Therapeutics | 1 | $20 |
| Abbott | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Bayer | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,464 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $87,091 |
| EliquisApixaban | 83 | $76,180 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $51,204 |
| MounjaroTirzepatide | 42 | $48,633 |
| JardianceEmpagliflozin | 51 | $47,659 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $43,798 |
| TrulicityDulaglutide | 38 | $41,213 |
| MyrbetriqMirabegron | 51 | $34,885 |
| LinzessLinaclotide | 38 | $23,276 |
| BelsomraSuvorexant | 39 | $19,232 |
| JanuviaSitagliptin Phosphate | 16 | $16,593 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $15,897 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $15,764 |
| FarxigaDapagliflozin Propanediol | 15 | $13,825 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $10,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $282 | $92,36693 claims |
| Novo NordiskOzempic | $217 | $87,09184 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $452 | $82,865113 claims |
| PfizerEliquis | $246 | $76,18083 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $29 | $57,37167 claims |
| MerckBelsomra, Januvia | $11 | $35,82655 claims |
| Astellas Pharma US IncMyrbetriq | $165 | $34,88551 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $697 | $29,07739 claims |
| AbbVieLinzess | $271 | $23,27638 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $3,830391 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Norman
- Lisa ConneryNorman$15.6M
- Steven CoxNorman$6.9M
- Rachel AndersonNorman$2.8M
- Carl GriffinOklahoma City$28.2M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Alexander FrankOklahoma City$3.1M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.